Glenmark Pharmaceuticals Limited (BOM:532296)
India · Delayed Price · Currency is INR | Market Cap | 654.11B +20.5% |
| Revenue (ttm) | 177.37B +32.9% |
| Net Income | 17.98B +138.5% |
| EPS | 63.69 +138.6% |
| Shares Out | n/a |
| PE Ratio | 36.38 |
| Forward PE | 27.46 |
| Dividend | 2.50 (0.11%) |
| Ex-Dividend Date | Aug 31, 2026 |
| Volume | 6,291 |
| Open | 2,339.95 |
| Previous Close | 2,325.00 |
| Day's Range | 2,304.85 - 2,346.60 |
| 52-Week Range | 1,794.00 - 2,471.05 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 2,497.73 (+8.31%) |
| Earnings Date | Jul 31, 2026 |
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injec... [Read more]
Financial Performance
In fiscal year 2026, Glenmark Pharmaceuticals's revenue was 170.43 billion, an increase of 27.53% compared to the previous year's 133.63 billion. Earnings were 13.62 billion, an increase of 30.06%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for 532296 stock is "Buy." The 12-month stock price target is ₹2,498, which is an increase of 8.31% from the latest price.
News
Glenmark Pharmaceuticals Transcript: Q1 26/27
Q1 FY 2027 saw 23% revenue growth year-over-year, led by strong performance in India, North America, and emerging markets. Margins held steady despite cost pressures, with guidance reaffirmed at 21%-22%. RYALTRIS and WINLEVI expanded globally, and new launches are set to drive future growth.
Glenmark Pharmaceuticals Quarterly report: Q1 2027
Glenmark Pharmaceuticals has published its Q1 2027 quarterly earnings report on August 2, 2026.
Glenmark Pharmaceuticals Slides: Q1 2027
Glenmark Pharmaceuticals has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 2, 2026.
India's Glenmark Pharma posts higher quarterly profit on strong demand
India's Glenmark Pharmaceuticals posted a 53.6% jump in adjusted first-quarter profit on Friday, led by strong demand for its drugs that treat long-term illnesses.
Pharma sector stocks today, July 6: Panacea Biotec surges 2.47%, Ajanta Pharma gains 1.48%, Glenmark Pharma up 1.29%
Indian pharmaceutical stocks showed mixed movements in early trading on July 6, 2026. The broader market indices recorded modest gains, with the Nifty 50 up 0.42% at 24,372.30 and the…
Glenmark Pharmaceuticals launches Olanzapine injection equivalent to Zyprexa
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. This new product is bioequival...
Pharma sector stocks today, July 2: Alembic Pharma falls 1.88%, Glenmark Pharma jumps 0.91%, Sun Pharma gains 0.67%
Indian pharma stocks showed mixed performance in early trading on July 2, 2026. The BSE Healthcare index rose 0.24% to 49,237.19, while the broader market also posted gains with the…
Glenmark Pharmaceuticals receives six observations from U.S. FDA inspection at Goa facility
Glenmark Pharmaceuticals Limited has announced that a recent inspection by the United States Food & Drug Administration (U.S. FDA) at its manufacturing facility in Goa resulted in the issuance of…
Glenmark Pharmaceuticals launches Methylene Blue Injection in the US market
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of its Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial. This new pro...
Glenmark launches Winlevi cream in key European markets for acne treatment
Glenmark Pharmaceuticals has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key European markets, marking its first introduction of a New Chemical Entity (NCE) in the region. Thi...
Top stocks for trade today, june 10: Bharti Airtel, Dixon Technologies, Vedanta, Glenmark Pharma, NLC India and more
Several companies are expected to remain in focus on June 10 following regulatory updates, project wins, business expansions, management changes, fundraising activities, and strategic investments. Pat...
Glenmark Pharmaceuticals Slides: FY 2026
Glenmark Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 9, 2026.
Why are Glenmark Pharma shares falling over 2% today? Explained
Shares of Glenmark Pharmaceuticals declined over 2% on Monday, June 1, despite the company reporting a strong set of Q4FY26 results and announcing a dividend for shareholders. The stock was…
Pharma Stocks Today, June 1: Wockhardt surges 12%, Natco Pharma crashes 6%, Glenmark Pharma down 3.63%
Pharmaceutical stocks traded mixed on June 1, 2026, during the early morning session. While a few stocks like Wockhardt and Sudeep Pharma posted strong gains, several others, including Natco Pharma…
Glenmark Pharmaceuticals Transcript: Q4 25/26
Q4 FY 2026 saw 15.8% YoY revenue growth and a landmark AbbVie licensing deal. Strong branded and global product expansion, debt-free status, and robust guidance for FY 2027 highlight the outlook, with India, emerging markets, and U.S. launches as key drivers.
Glenmark Pharmaceuticals Quarterly report: Q4 2026
Glenmark Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 31, 2026.
Glenmark Pharmaceuticals Slides: Q4 2026
Glenmark Pharmaceuticals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 31, 2026.
Glenmark Pharmaceuticals Annual report: Q4 2026
Glenmark Pharmaceuticals has published its Q4 2026 annual report on May 31, 2026.
IndiGo, Glenmark Pharma, Lupin, NMDC, Olectra Greentech, PNC Infratech, NMDC shares in focus today, June 1
Several stocks are expected to remain in focus on June 1 following quarterly earnings announcements, regulatory approvals, government policy measures and fresh order wins. Companies including InterGlo...
Glenmark Pharma shares is focus today after Q4 profit surges 64 times, EBITDA up 35.9%
Shares of Glenmark Pharmaceuticals are expected to remain in focus on Monday after the pharmaceutical major reported a massive jump in consolidated net profit for the fourth quarter of FY26,…
Top Q4 results today, May 29: Asian Paints, BEML, IndiGo, Glenmark Pharma, NMDC among key companies to announce earnings
More than 700 listed companies are scheduled to announce their Q4FY26 earnings on May 29, reporting financial performance for the January–March 2026 quarter. Investors and market participants will clo...
Pharma Sector Stocks Today, May 25: Torrent Pharma up 4.23%, Glenmark Pharma gains 4%, Sun Pharma down 0.31%
The pharmaceutical sector showed mixed performance on May 25, 2026, during the early morning trade. The broader market remained positive with the Nifty 50 rising 0.92% to 23,937.85 as of…
Top stocks for trade today, May 21: Ola Electric, Aditya Birla Capital, Jubilant FoodWorks, Apollo Hospitals, Glenmark Pharma and more
Several companies are likely to remain in focus on May 21 following quarterly earnings, fundraising announcements, order wins, project developments, and business updates. Ola Electric Shares of Ola El...
Glenmark Pharma shares in focus today after IGI unveils new cancer therapy candidate ISB 2301
Shares of Glenmark Pharmaceuticals are likely to remain in focus on Thursday after its innovation arm, Ichnos Glenmark Innovation (IGI), announced a new development candidate, ISB 2301, aimed at treat...
Glenmark unveils ISB 2301, a groundbreaking multispecific immune activator for solid tumours
Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company, has announced its latest development candidate, ISB 2301. This first-in-class, multispecific immune cells activat...